Humacyte (HUMA) Total Non-Current Liabilities (2020 - 2026)

Humacyte (HUMA) has 7 years of Total Non-Current Liabilities data on file, last reported at $88.1 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $88.1 million, down 28.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.1 million (down 28.4% YoY), and the FY2025 annual result was $101.8 million, down 14.9% from the prior year.
• Total Non-Current Liabilities fell to $88.1 million in Q1 2026 per HUMA's latest filing, from $101.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $134.5 million in Q1 2024 and troughed at $59.0 million in Q1 2023.
• A 5-year average of $96.6 million and a median of $101.8 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities soared 2558.66% in 2022, then dropped 28.4% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $87.4 million in 2022, then surged by 31.16% to $114.6 million in 2023, then rose by 4.35% to $119.6 million in 2024, then fell by 14.9% to $101.8 million in 2025, then decreased by 13.43% to $88.1 million in 2026.
• Business Quant data shows HUMA's Total Non-Current Liabilities at $88.1 million in Q1 2026, $101.8 million in Q4 2025, and $74.5 million in Q3 2025.